Published in Antimicrob Agents Chemother on July 01, 2002
H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut (2004) 4.66
Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev (2007) 3.43
Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther (2015) 1.22
Eradication of Helicobacter pylori: a clinical update. MedGenMed (2004) 1.20
High-level beta-lactam resistance associated with acquired multidrug resistance in Helicobacter pylori. Antimicrob Agents Chemother (2003) 1.09
Antimicrobial susceptibility of Helicobacter pylori strains isolated in Bangladesh. J Clin Microbiol (2004) 1.03
Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance. Dig Dis Sci (2014) 0.95
Antimicrobial susceptibility and resistance patterns among Helicobacter pylori strains from The Gambia, West Africa. Antimicrob Agents Chemother (2012) 0.93
Current recommendations for Helicobacter pylori therapies in a world of evolving resistance. Gut Microbes (2013) 0.92
Who's Winning the War? Molecular Mechanisms of Antibiotic Resistance in Helicobacter pylori. Curr Drug ther (2008) 0.92
Discovery of novel mutations for clarithromycin resistance in Helicobacter pylori by using next-generation sequencing. J Antimicrob Chemother (2014) 0.86
Search for novel candidate mutations for metronidazole resistance in Helicobacter pylori using next-generation sequencing. Antimicrob Agents Chemother (2015) 0.85
Resistance mechanisms in an in vitro-selected amoxicillin-resistant strain of Helicobacter pylori. Antimicrob Agents Chemother (2006) 0.83
Contribution of specific amino acid changes in penicillin binding protein 1 to amoxicillin resistance in clinical Helicobacter pylori isolates. Antimicrob Agents Chemother (2010) 0.83
Worldwide Population Structure, Long-Term Demography, and Local Adaptation of Helicobacter pylori. Genetics (2015) 0.82
Substitutions in penicillin-binding protein 1 in amoxicillin-resistant Helicobacter pylori strains isolated from Korean patients. Gut Liver (2013) 0.82
Virulence determinants, drug resistance and mobile genetic elements of Laribacter hongkongensis: a genome-wide analysis. Cell Biosci (2011) 0.78
Effect of licorice versus bismuth on eradication of Helicobacter pylori in patients with peptic ulcer disease. Pharmacognosy Res (2014) 0.75
The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature (1997) 34.00
Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med (1991) 23.89
Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori. Nature (1999) 19.34
beta-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev (1995) 12.53
Helicobacter pylori. Clin Microbiol Rev (1997) 9.22
A standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain. Gastroenterology (1997) 7.72
Metronidazole resistance in Helicobacter pylori is due to null mutations in a gene (rdxA) that encodes an oxygen-insensitive NADPH nitroreductase. Mol Microbiol (1998) 3.44
Transformation of Helicobacter pylori by chromosomal metronidazole resistance and by a plasmid with a selectable chloramphenicol resistance marker. J Gen Microbiol (1993) 3.39
Penicillin-binding proteins of gram-negative bacteria. Rev Infect Dis (1988) 3.38
Ecology of Helicobacter pylori in the human stomach. J Clin Invest (1997) 2.77
Evaluation of the E test for quantitative antimicrobial susceptibility testing of Helicobacter pylori. J Clin Microbiol (1991) 2.26
Stable amoxicillin resistance in Helicobacter pylori. Lancet (1998) 2.20
Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study. Antimicrob Agents Chemother (1999) 2.07
Resistance of helicobacter pylori to metronidazole, tetracycline and amoxycillin. J Antimicrob Chemother (2000) 1.44
Formation of potent hybrid promoters of the mutant llm gene by IS256 transposition in methicillin-resistant Staphylococcus aureus. J Bacteriol (1997) 1.44
Comparison of the Etest and the NCCLS-approved agar dilution method to detect metronidazole and clarithromycin resistant Helicobacter pylori. Int J Antimicrob Agents (2001) 1.39
Amoxycillin tolerance in Helicobacter pylori. J Antimicrob Chemother (1999) 1.38
Characterization of an In vitro-selected amoxicillin-resistant strain of Helicobacter pylori. Antimicrob Agents Chemother (2000) 1.12
Different penicillin-binding protein profiles in amoxicillin-resistant Helicobacter pylori. Helicobacter (1999) 1.10
Competition of various beta-lactam antibiotics for the major penicillin-binding proteins of Helicobacter pylori: antibacterial activity and effects on bacterial morphology. Antimicrob Agents Chemother (1999) 1.10
Mutations of the Helicobacter pylori genes rdxA and pbp1 cause resistance against metronidazole and amoxicillin. Antimicrob Agents Chemother (2001) 1.02
Round-cell mutants of Salmonella typhimurium produced by transposition mutagenesis: lethality of rodA and mre mutations. Mol Gen Genet (1993) 1.00
The cysteine-rich protein A from Helicobacter pylori is a beta-lactamase. J Biol Chem (2000) 0.98
Identification of a novel penicillin-binding protein from Helicobacter pylori. J Bacteriol (1999) 0.95
Antimicrobial treatment of Helicobacter pylori infection. Clin Infect Dis (1997) 0.94
Use of digoxigenin-labelled ampicillin in the identification of penicillin-binding proteins in Helicobacter pylori. J Antimicrob Chemother (2000) 0.94
Discrepancies between E-test and agar dilution methods for testing metronidazole susceptibility of Helicobacter pylori. J Clin Microbiol (1998) 0.87
Cloning and characterization of the lytB gene of Campylobacter jejuni. FEMS Microbiol Lett (1997) 0.84
Subpopulations of Helicobacter pylori are responsible for discrepancies in the outcome of nitroimidazole susceptibility testing. Antimicrob Agents Chemother (1999) 0.84
Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut (2006) 9.03
Low prevalence of methicillin-resistant Staphylococcus aureus (MRSA) at hospital admission in the Netherlands: the value of search and destroy and restrictive antibiotic use. J Hosp Infect (2004) 3.69
Salmonella typhimurium loci involved in survival within macrophages. Infect Immun (1994) 3.32
[Occult blood studies of the feces obsolete]. Ned Tijdschr Geneeskd (1996) 3.29
Nurse endoscopists perform colonoscopies according to the international standard and with high patient satisfaction. Endoscopy (2012) 3.27
Helicobacter pylori eradication and gastric cancer: when is the horse out of the barn? Am J Gastroenterol (2009) 2.89
Potential role of molecular mimicry between Helicobacter pylori lipopolysaccharide and host Lewis blood group antigens in autoimmunity. Infect Immun (1996) 2.75
Colonoscopy perforation rate, mechanisms and outcome: from diagnostic to therapeutic colonoscopy. Endoscopy (2009) 2.70
Diagnostic tests for Helicobacter pylori: a prospective evaluation of their accuracy, without selecting a single test as the gold standard. Am J Gastroenterol (1996) 2.65
Complications of single-balloon enteroscopy: a prospective evaluation of 166 procedures. Endoscopy (2010) 2.62
Short-term esophageal stenting in the management of benign perforations. Am J Gastroenterol (2010) 2.55
Double-balloon enteroscopy: indications, diagnostic yield, and complications in a series of 275 patients with suspected small-bowel disease. Endoscopy (2006) 2.43
Mechanism of clarithromycin resistance in clinical isolates of Helicobacter pylori. FEMS Microbiol Lett (1996) 2.42
Quasispecies development of Helicobacter pylori observed in paired isolates obtained years apart from the same host. J Infect Dis (2000) 2.42
Increasing incidence of Barrett's oesophagus in the general population. Gut (2005) 2.34
Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease. Am J Gastroenterol (1999) 2.33
High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol (2010) 2.32
Stable amoxicillin resistance in Helicobacter pylori. Lancet (1998) 2.20
Omeprazole as a diagnostic tool in gastroesophageal reflux disease. Am J Gastroenterol (1997) 2.17
The incidence of Barrett's oesophagus and oesophageal adenocarcinoma in the United Kingdom and The Netherlands is levelling off. Aliment Pharmacol Ther (2014) 2.07
The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol (2009) 2.04
The pef fimbrial operon of Salmonella typhimurium mediates adhesion to murine small intestine and is necessary for fluid accumulation in the infant mouse. Infect Immun (1996) 2.04
[Acute dysphasia: often there is a readily treatable cause]. Ned Tijdschr Geneeskd (2003) 2.03
A comparison of 3 types of covered metal stents for the palliation of patients with dysphagia caused by esophagogastric carcinoma: a prospective, randomized study. Gastrointest Endosc (2001) 2.03
Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia. Am J Gastroenterol (2012) 1.98
Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. Br J Cancer (2009) 1.93
Long-term esophageal cancer risk in patients with primary achalasia: a prospective study. Am J Gastroenterol (2010) 1.85
Systematic review: the global incidence and prevalence of peptic ulcer disease. Aliment Pharmacol Ther (2009) 1.83
Optimal resource allocation in colonoscopy: timing of follow-up colonoscopies in relation to adenoma detection rates. Endoscopy (2013) 1.82
The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: a meta-analysis. Am J Gastroenterol (1999) 1.77
The detection, surveillance and treatment of premalignant gastric lesions related to Helicobacter pylori infection. Helicobacter (2007) 1.77
Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin, tetracycline and trovafloxacin in The Netherlands. J Antimicrob Chemother (1999) 1.73
Helicobacter pylori: a true carcinogen? Eur J Gastroenterol Hepatol (1998) 1.72
Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer (2008) 1.69
Time-trends in gastroprotection with nonsteroidal anti-inflammatory drugs (NSAIDs). Aliment Pharmacol Ther (2010) 1.68
Regulation of ferritin-mediated cytoplasmic iron storage by the ferric uptake regulator homolog (Fur) of Helicobacter pylori. J Bacteriol (2000) 1.66
Parietal cell protrusions and fundic gland cysts during omeprazole maintenance treatment. Hum Pathol (2000) 1.62
Helicobacter pylori and the birth cohort effect: evidence of a continuous decrease of infection rates in childhood. Am J Gastroenterol (1997) 1.62
Hypergastrinaemia during long-term omeprazole therapy: influences of vagal nerve function, gastric emptying and Helicobacter pylori infection. Aliment Pharmacol Ther (1998) 1.61
Clinical outcome of progressive stenting in patients with anastomotic strictures after orthotopic liver transplantation. Endoscopy (2013) 1.61
Accurate prediction of macrolide resistance in Helicobacter pylori by a PCR line probe assay for detection of mutations in the 23S rRNA gene: multicenter validation study. Antimicrob Agents Chemother (2001) 1.60
Systematic review: Rebound acid hypersecretion after therapy with proton pump inhibitors. Aliment Pharmacol Ther (2007) 1.59
Nickel-responsive induction of urease expression in Helicobacter pylori is mediated at the transcriptional level. Infect Immun (2001) 1.59
comH, a novel gene essential for natural transformation of Helicobacter pylori. J Bacteriol (2000) 1.57
Explaining the bias in the 23S rRNA gene mutations associated with clarithromycin resistance in clinical isolates of Helicobacter pylori. Antimicrob Agents Chemother (1998) 1.56
Prevalence of autoimmune pancreatitis and other benign disorders in pancreatoduodenectomy for presumed malignancy of the pancreatic head. Dig Dis Sci (2012) 1.56
Comparative genomic hybridisation. Mol Pathol (1999) 1.56
Predictors of dose escalation of adalimumab in a prospective cohort of Crohn's disease patients. Aliment Pharmacol Ther (2011) 1.53
Phase variation in Helicobacter pylori lipopolysaccharide due to changes in the lengths of poly(C) tracts in alpha3-fucosyltransferase genes. Infect Immun (1999) 1.51
Rapid quantitative assessment of gastric corpus atrophy in tissue sections. J Clin Pathol (2001) 1.50
Changes in the vaginal flora after two percent clindamycin vaginal cream in women at high risk of spontaneous preterm birth. BJOG (2001) 1.50
Antigenicity of the peplomer protein of infectious bronchitis virus. Mol Immunol (1989) 1.49
Insertion of mini-IS605 and deletion of adjacent sequences in the nitroreductase (rdxA) gene cause metronidazole resistance in Helicobacter pylori NCTC11637. Antimicrob Agents Chemother (1999) 1.48
[Palliative treatment of esophageal cancer with dysphagia: more favourable outcome from single-dose internal brachytherapy than from the placement of a self-expanding stent; a multicenter randomised study]. Ned Tijdschr Geneeskd (2005) 1.48
Sequential therapy; a new treatment for Helicobacter pylori infection. But is it ready for general use? Dig Liver Dis (2004) 1.47
Evidence for a conjugation-like mechanism of DNA transfer in Helicobacter pylori. J Bacteriol (1998) 1.47
Grading of dysplasia in Barrett's oesophagus: substantial interobserver variation between general and gastrointestinal pathologists. Histopathology (2007) 1.47
Identification of loci essential for the growth of Helicobacter pylori under acidic conditions. J Infect Dis (2000) 1.45
European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication. Endoscopy (2012) 1.44
Comparison of magnetic resonance enteroclysis and capsule endoscopy with balloon-assisted enteroscopy in patients with obscure gastrointestinal bleeding. Endoscopy (2012) 1.44
The NordICC Study: rationale and design of a randomized trial on colonoscopy screening for colorectal cancer. Endoscopy (2012) 1.44
[Double-balloon enteroscopy of the small intestine]. Ned Tijdschr Geneeskd (2007) 1.43
The accuracy of the Helicobacter pylori stool antigen test in diagnosing H. pylori in treated and untreated patients. Eur J Gastroenterol Hepatol (2001) 1.43
Helicobacter pylori ribBA-mediated riboflavin production is involved in iron acquisition. J Bacteriol (1998) 1.42
[Diagnosis and treatment of esophageal cancer in the Netherlands: wide variation in the second line]. Ned Tijdschr Geneeskd (2003) 1.40
High prevalence of ESBL-producing Enterobacteriaceae carriage in Dutch community patients with gastrointestinal complaints. Clin Microbiol Infect (2012) 1.40
The importance of vacA, cagA, and iceA genotypes of Helicobacter pylori infection in peptic ulcer disease and gastroesophageal reflux disease. Am J Gastroenterol (2001) 1.40
Hemospray in the treatment of upper gastrointestinal hemorrhage in patients on antithrombotic therapy. Endoscopy (2012) 1.40
Helicobacter pylori, acid, and omeprazole revisited: bacterial eradication and rebound hypersecretion. Gastroenterology (1999) 1.40
[Incidental cystic structures in the upper abdomen: to remove or not to remove?]. Ned Tijdschr Geneeskd (2006) 1.39
Country-specific constancy by age in cagA+ proportion of Helicobacter pylori infections. Int J Cancer (1997) 1.38
Multiplicity in polyp count and extracolonic manifestations in 40 Dutch patients with MYH associated polyposis coli (MAP). J Med Genet (2005) 1.38
[Gastrojejunostomy versus endoscopic stent placement as palliative treatment of malignant stenosis of the duodenum: overview of advantages and disadvantages on the basis of a literature study]. Ned Tijdschr Geneeskd (2007) 1.38
5-aminolevulinic acid photodynamic therapy versus argon plasma coagulation for ablation of Barrett's oesophagus: a randomised trial. Gut (2004) 1.37
Percutaneous endoscopic gastrostomy: complications and suggestions to avoid them. Eur J Gastroenterol Hepatol (2001) 1.37
Predictors for neoplastic progression in patients with Barrett's Esophagus: a prospective cohort study. Am J Gastroenterol (2011) 1.36
Polymorphisms of Helicobacter pylori HP0638 reflect geographic origin and correlate with cagA status. J Clin Microbiol (2002) 1.35
Optimal preparation for video capsule endoscopy: a prospective, randomized, single-blind study. Endoscopy (2007) 1.35
Presence of Helicobacter pylori in the oral cavity, oesophagus, stomach and faeces of patients with gastritis. Eur J Clin Microbiol Infect Dis (1995) 1.35
Importance of the fiberoptic endoscope cleaning procedure for detection of Helicobacter pylori in gastric biopsy specimens by PCR. J Clin Microbiol (1994) 1.32
Declining incidence of peptic ulcer but not of its complications: a nation-wide study in The Netherlands. Aliment Pharmacol Ther (2006) 1.32
Rapid detection, by PCR and reverse hybridization, of mutations in the Helicobacter pylori 23S rRNA gene, associated with macrolide resistance. Antimicrob Agents Chemother (1999) 1.30
The mannose cap of mycobacterial lipoarabinomannan does not dominate the Mycobacterium-host interaction. Cell Microbiol (2007) 1.29
Inactivation of a Serpula (Treponema) hyodysenteriae hemolysin gene by homologous recombination: importance of this hemolysin in pathogenesis in mice. FEMS Microbiol Lett (1992) 1.27
The use of genetic testing in hereditary colorectal cancer syndromes: genetic testing in HNPCC, (A)FAP and MAP. Clin Genet (2007) 1.27
Nosocomial infections in a Dutch neonatal intensive care unit: surveillance study with definitions for infection specifically adapted for neonates. J Hosp Infect (2005) 1.26
Rapid screening of methicillin-resistant Staphylococcus aureus using PCR and chromogenic agar: a prospective study to evaluate costs and effects. Clin Microbiol Infect (2010) 1.25
Esophagopleural fistula treated endoscopically with argon beam electrocoagulation and clips. Gastrointest Endosc (1999) 1.24
Identification of virulence genes of Helicobacter pylori by random insertion mutagenesis. Infect Immun (1999) 1.23